Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat in pediatric anemia of chronic kidney disease after ESA conversion
2021-004022-30Phase 3Terminated
- Sponsor
- Akebia Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vadadustat in anemia of chronic kidney disease and anaemia, sponsored by Akebia Therapeutics. Primary endpoint: Mean change in hemoglobin between baseline and Weeks 21–28. Started Dec 2021; status: terminated.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney diseaseanaemia
Beyond the preview
Go deeper on 2021-004022-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004022-30.